Definitive Healthcare (NASDAQ:DH) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Definitive Healthcare (NASDAQ:DH) from a buy rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

DH has been the topic of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st. Bank of America reiterated an “underperform” rating and set a $0.70 price target on shares of Definitive Healthcare in a research report on Monday, June 29th. Morgan Stanley cut their price objective on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a report on Tuesday, August 11th. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a research report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $1.00 target price on shares of Definitive Healthcare in a research note on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $1.47.

Definitive Healthcare Stock Up 1.0%

Shares of NASDAQ:DH opened at $1.05 on Friday. The firm has a fifty day moving average price of $0.76 and a two-hundred day moving average price of $0.94. The company has a market cap of $112.08 million, a price-to-earnings ratio of -0.66, a PEG ratio of 12.96 and a beta of 1.40. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.86 and a quick ratio of 1.86. Definitive Healthcare has a one year low of $0.61 and a one year high of $4.35.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings results on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. The firm had revenue of $55.20 million for the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Analysts anticipate that Definitive Healthcare will post 0.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its position in shares of Definitive Healthcare by 32.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after purchasing an additional 4,407 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Definitive Healthcare by 5.8% during the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after buying an additional 6,400 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Definitive Healthcare during the 2nd quarter valued at about $32,000. Creative Planning lifted its position in Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after buying an additional 8,428 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Definitive Healthcare in the 4th quarter worth approximately $35,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.